Brief: Petros Pharmaceuticals Expands Program For Peyronie's Disease Investigational Treatment
08/11/2021 14:19
Nov 8 (Reuters) - Petros Pharmaceuticals Inc PTPI.O :
* PETROS PHARMACEUTICALS EXPANDS PROGRAM FOR NOVEL
INVESTIGATIONAL
NON-INVASIVE TREATMENT FORMULATION FOR PEYRONIE'S DISEASE
* PETROS PHARMACEUTICALS INC - EXCLUSIVE GLOBAL LICENSE
AGREEMENT
WITH HYBRID MEDICAL LLC
Source text for Eikon: ID:nPnc8W8M3a
Further company coverage: PTPI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Petros Pharmaceuticals
See all newsBrief: Petros Pharmaceuticals Assigns All Assets To Pt Liquidation, For Benefit Of Creditors
Brief: Petros Pharmaceuticals’ STENDRA Pivotal Consumer Self-Selection Study for Over-the-Counter Access Demonstrates Statistical Significance
Brief: Petros Pharmaceuticals Files For Mixed Shelf Of Up To $100 Million - SEC Filing
Brief: Petros Pharmaceuticals Expands Online Distribution For Prescription STENDRA(R) Through New Agreement With Lemonaid Health
Brief: Petros Pharma Announces Partnership with Idea Evolver for Rx-to-OTC Switches & Digital Launch Solutions